CVSI · CV Sciences, Inc.

CV Sciences’ Q1 2026 results reflect ongoing operational stabilization amid persistent regulatory headwinds: revenue declined 11.4% YoY to $3.2 million, primarily due to reduced unit volume stemming from restrictive federal and state hemp regulations — a structural challenge explicitly cited by management. Despite lower top-line, gross margin expanded 290 bps to 48.9%, indicating progress in optimizing product mix and cost structure. Operating expenses were reduced 13.3% YoY (excluding a $0.5M payroll tax reversal in Q1 2025), contributing to a narrowed adjusted EBITDA loss of $0.1 million — an improvement from $0.3 million loss in Q1 2025 and a sequential swing from $0.1 million positive in Q4 2025. However, liquidity remains strained: cash stood at $0.3 million as of March 31, 2026 — down from $0.8 million a year earlier — underscoring the urgency of the recently completed debt restructuring, which management stated improves financial flexibility and positions the company for strategic growth, including selective acquisitions. CEO Joseph Dowling emphasized expectations for further gross margin improvement in H2 2026 and reiterated commitment to disciplined expense management and path to sustainable profitability and positive cash flow — though no quantitative guidance was provided. The press release also disclosed that 43% of Q1 2026 net revenue came from 45 new products launched since January 2023, highlighting innovation as a key lever amid market constraints.